Related by context. All words. (Click for frequent words.) 71 ONTARGET 70 RE LY 70 Prospective Randomized 70 RE MODEL 69 RE LY ® 68 phase IIIb 67 Randomized Clinical Trial 67 multicenter randomized clinical 67 ONTARGET R 67 multicenter prospective 66 Fondaparinux 66 Betaferon R 66 STRIDE PD 66 Randomized Evaluation 66 REALITY Trial 66 placebo controlled clinical 66 multicenter randomized controlled 66 multicentre randomized 66 LUMINATE 65 Celecoxib APC trial 65 Catena ® 65 Trandolapril 65 Acute Myocardial Infarction 65 Study Evaluating 65 icatibant 65 prospective multicenter 65 Pivotal Trial 65 Stenting Trial CREST 65 LUX Lung 65 EURIDIS 65 Patency 65 Tiotropium 65 Prolongs Survival 65 HuMax EGFr 65 BCIRG 64 Prospective Multicenter 64 Multicenter 64 Randomised 64 recurrent glioma 64 Phase III Clinical Trial 64 Carotid Revascularization Endarterectomy vs. 64 prospective randomized multicenter 64 sunitinib malate 64 Platelet Inhibition 64 multicentre randomized controlled 64 Aggressive Reduction 64 prospective randomized controlled 64 Investigator Initiated 64 Acute Ischemic Stroke 64 Patient Outcomes 64 Ischemic Stroke 64 Hormone Refractory Prostate Cancer 64 Juvenile Idiopathic Arthritis 64 relapsing multiple sclerosis 64 Pemetrexed 64 Severe Sepsis 64 Long Term Efficacy 64 direct thrombin inhibitors 64 Ranolazine 64 Phase IIB 64 Restenosis 64 ENGAGE AF TIMI 64 STENT 64 prospective multicentre 64 Randomized controlled 64 CIMZIA TM certolizumab pegol 64 Clinical Outcome 64 ENESTnd 64 randomized Phase IIb 63 carotid artery stenting CAS 63 Scandinavian Simvastatin Survival 63 Valsartan 63 EchoCRT 63 See CLINICAL PHARMACOLOGY 63 multicenter multinational 63 venous thromboembolic disease 63 Cholesterol Levels SPARCL 63 Prostate AdenoCarcinoma Treatment 63 unfractionated heparin UFH 63 oral FTY# 63 Advanced Melanoma 63 Intervention Trial 63 Vascugel ® 63 relapsed MM 63 RESOLUTE clinical 63 ACE Inhibitors 63 colesevelam HCl 63 Monotherapy 63 Pirfenidone 63 velafermin 63 Adenoma Prevention 63 Adjuvant Treatment 63 Ozarelix 63 Phase IIIb clinical 63 Protelos 63 Pivotal Clinical Trial 63 Zenvia Phase III 63 Tipranavir 63 Thrombolysis 63 Dual Antiplatelet Therapy 63 Rheumatoid Arthritis Patients 63 Betaferon ® 63 Relapsing Remitting Multiple Sclerosis 63 Cilostazol 63 Adjuvant Therapy 63 Pivotal Phase III 63 Meets Primary Endpoint 63 pain palliation 63 EVEREST II 63 gefitinib Iressa 63 Metastatic Prostate Cancer 63 randomized multicenter trial 63 lapatinib Tykerb 63 Carotid Stenting 63 TLK# 63 Phase Ib clinical 63 Advanced Renal Cell 63 Oral Fingolimod 63 Pooled Analysis 63 Intervention Effectiveness 63 Bivalirudin 63 Subgroup Analysis 63 ST Segment Elevation 62 Fracture Intervention Trial 62 ARIXTRA 62 Ovarian Cancer Screening 62 Edge STudy 62 Phase III Pivotal 62 FASLODEX 62 sorafenib Nexavar 62 DAPT Study 62 Fulvestrant 62 Tocilizumab 62 Gastric Cancer 62 Phase IIIb 62 Pertuzumab 62 TRANSCEND 62 phase IIa clinical 62 Digital Mammographic Imaging 62 Combination Treatment 62 blinded randomized placebo controlled 62 Catheter Ablation 62 glatiramer acetate 62 Randomized Double Blind 62 Unfractionated Heparin 62 ZACTIMA 62 Phase IIb Trial 62 Cardiotoxicity 62 Adjuvant Chemotherapy 62 Carotid Endarterectomy 62 BRIM2 62 randomized multicenter 62 dabigatran etexilate 62 ACTEMRA TM 62 Decompensated Heart Failure 62 Ischemic 62 Phase III Clinical Trials 62 Hepatocellular Carcinoma 62 docetaxel Taxotere ® 62 First Patient Enrolled 62 TMC# C# 62 APTIVUS 62 Chronic Sinusitis 62 ASTEROID 62 Venous Thromboembolism 62 Oral Mucositis 62 BENICAR HCT 62 prospective randomized placebo 62 Tumor Response 62 Demonstrates Efficacy 62 Renal Artery 62 Glypromate 62 Aflibercept 62 II Clinical Trial 62 subanalysis 62 Clinical Trial Evaluating 62 assessing T DM1 62 Acute Heart Failure 62 Acute Decompensated Heart Failure 62 Protease Inhibitor 62 MYCAMINE 62 Mitomycin C 62 prospective multicenter randomized 62 Catheter Associated 62 Refractory Angina 62 Cardiovascular Events 62 DU #b 62 Mycophenolate Mofetil 62 Infarct 62 Metastatic Colorectal Cancer 62 Myocardial Ischemia 62 Bosutinib 62 CARE HF 62 Newly Diagnosed Multiple Myeloma 62 REMINYL ® 62 tipranavir 62 Acute Coronary Syndromes 62 Nitinol Stent 62 DAPT 62 lexidronam injection 62 Percutaneous Tibial Nerve Stimulation 62 Traficet EN 62 Left Ventricular Dysfunction 62 AIM HIGH 62 invasive candidiasis 62 relapsing remitting MS RRMS 62 Glatiramer Acetate 62 Left Ventricular 62 RELOVAIR ™ 62 Percutaneous Coronary Intervention 62 Dasatinib 62 Dose Ranging Study 62 Pharmacokinetic Study 62 CHAMPION PCI 62 ACCOMPLISH 62 Is Well Tolerated 62 Shows Efficacy 62 Protease Inhibitors 62 HCV SPRINT 62 tolerability pharmacokinetics 62 BRIM3 61 Aliskiren 61 Phase 2b Study 61 Multiple Ascending Dose 61 Pivotal Phase 61 Diabetic Macular Edema 61 Placebo Controlled Trial 61 Antiplatelet 61 pertuzumab 61 MIST II 61 registrational Phase 61 Combination Therapy 61 Peginterferon 61 Lung Cancer Trial 61 FDA APPROVES 61 Neoadjuvant 61 Aggrenox ® 61 Controlled Trial 61 Eculizumab 61 standard chemotherapy regimen 61 Aortic Dissection 61 Pivotal Trials 61 ADMIRE HF 61 Aortic Stenosis 61 double blinded randomized 61 Phase 2b Clinical Trial 61 fosbretabulin 61 ORENCIA ® 61 Aneurysm Repair 61 ADVANCE PD 61 JAK Inhibitor 61 CLARITY TIMI 61 Phase 2a Clinical Trial 61 treatment naive genotype 61 Golimumab 61 Septic Shock 61 CYPHER ® 61 Efficacy Trial 61 Double Blind Placebo 61 Pulmonary Arterial Hypertension 61 NSABP B 61 Val HeFT 61 Venous Thrombosis 61 Ridaforolimus 61 Exemestane 61 Diabetic Neuropathy 61 Non Alcoholic Steatohepatitis 61 Initiated Phase 61 Recurrent Stroke 61 Rilonacept 61 Schizophrenia Treatment 61 Complicated Skin 61 Alfimeprase 61 Temsirolimus 61 Apixaban 61 Pegylated Interferon 61 acadesine 61 Degarelix 61 Surgical Treatment 61 ExTRACT TIMI 61 Patients Treated With 61 TAXUS ATLAS 61 multicenter Phase II 61 Cardiac Allograft Rejection 61 HER2 Positive Breast Cancer 61 Sustained Virologic Response 61 angiotensin receptor blocker ARB 61 Anticoagulant 61 PROTEGE 61 Telmisartan 61 multicenter randomized placebo controlled 61 EINSTEIN DVT 61 interferon ribavirin 61 Phase III multicenter 61 Recurrent Glioblastoma 61 Randomized Controlled Trials 61 HORIZONS AMI 61 Diabetic Patients 61 Rosuvastatin 61 Soft Tissue Sarcoma 61 HCV RESPOND 2 61 phase Ib 61 phase IIa 61 Patients Treated 61 Trastuzumab 61 Rivaroxaban 61 Sirolimus eluting 61 ancrod 61 PRECISE 61 Phase III Trial 61 multicenter placebo controlled 61 Moxifloxacin 61 Cardiovascular Outcomes 61 Bare Metal Stent 61 ABSORB trial 61 multicenter phase 61 multicenter randomized 61 CIPN 61 Epoetin Alfa 61 rosuvastatin Crestor 61 aripiprazole Abilify 61 invasive aspergillosis 61 oral deforolimus 61 dual endothelin receptor antagonist 61 Spine Patient Outcomes 61 Adalimumab 61 COPAXONE R 61 ToGA 61 riociguat 61 Resistant Hypertension 61 Xelox 61 Irinotecan 61 Bosentan 61 Relapsing Multiple Sclerosis 61 APTIVUS r 61 Breast Density 61 CLARITY study 61 Treated Patients 61 placebo controlled Phase 61 Improved Survival 61 pegylated interferon alfa 2b 61 Tanespimycin 61 CINQUIL 61 ATACAND 60 Recurrent Breast Cancer 60 Randomized Phase II 60 rosuvastatin #mg 60 #mg BID [001] 60 Ziprasidone 60 Sapacitabine 60 Clostridium difficile Infection 60 Preclinical Study 60 Chronic Heart Failure 60 SWOG 60 Phase Ib II 60 Deforolimus 60 Antiplatelet Therapy 60 desvenlafaxine succinate 60 Anticoagulation 60 AVASTIN 60 active comparator 60 NATRECOR R 60 Toremifene 60 Fungal Infections 60 Thromboembolism 60 Combination REOLYSIN R 60 Eluting Coronary Stent System 60 Randomized Phase 60 Meta Analysis 60 Autologous Stem Cell Transplantation 60 ACTIVE W 60 recurrent glioblastoma multiforme 60 dose escalation clinical 60 Treating Chronic 60 ENDEAVOR IV 60 Phase Ib Clinical Trial 60 clopidogrel Plavix 60 Lipid Lowering 60 canakinumab 60 Helicobacter pylori eradication 60 Zemplar Capsules 60 cardio renal 60 prospective multicenter study 60 Survival Benefit 60 Randomized Double blind 60 Antiepileptic Drug 60 Screening Trial 60 prospectively randomized 60 Hepatocellular Carcinoma HCC 60 Stent Thrombosis 60 Randomized Study 60 TRANSFORMS 60 BARI 2D 60 Eluting Stent 60 Cethromycin 60 GW# [003] 60 CALGB # [002] 60 ReoPro 60 Blinatumomab 60 Acute Stroke 60 Improves Outcomes 60 Asthma Intervention 60 MAGE A3 ASCI 60 reslizumab 60 Multicenter Automatic Defibrillator Implantation 60 Enzyme Replacement Therapy 60 Knee Osteoarthritis 60 Statistically Significant 60 INSPIRE Trial Phase III 60 confirmatory clinical 60 telmisartan 60 Cardiac Resynchronization 60 Bazedoxifene 60 GISSI 60 placebo controlled Phase III 60 PREZISTA r 60 Acute Coronary Syndromes ACS 60 Pivotal Study 60 HF ACTION 60 HPTN 60 Kidney Transplant Patients 60 antiplatelet agent 60 bevacizumab Avastin 60 Diabetic Foot Ulcer 60 tocilizumab 60 peg interferon 60 VADT 60 Women Ischemia Syndrome 60 GP IIb IIIa inhibitors 60 ritonavir boosted 60 KRN# 60 Teriparatide 60 Nesiritide 60 EQUIP OB 60 Confirms Efficacy 60 Severe Asthma 60 VFEND 60 nab paclitaxel 60 Long Lesion 60 Intervention Effectiveness CATIE 60 Natalizumab 60 ARCOXIA 60 Intravitreal 60 Demonstrates Sustained 60 Fracture Risk 60 Combo Therapy 60 SCD HeFT 60 vorinostat 60 CYT# potent vascular disrupting 60 Relapsed Multiple Myeloma 60 Afatinib 60 Celebrex celecoxib 60 Drug Eluting Stents 60 multicentre 60 ACRIN 60 Mg Usa 60 Ophena 60 Dabigatran 60 Nilotinib 60 MoxDuo TM IR 60 ZOLINZA 60 Patients Receiving 60 NeuroStar TMS Therapy 60 PRADAXA 60 Invasive Breast Cancer 60 Olmesartan 60 Phase III Trials 60 visilizumab 60 International Verapamil SR 60 Overactive Bladder 60 Coronary Artery Bypass Graft 60 ASPIRE HIGHER 60 CERVARIX 60 PHASE III 60 Antiviral Activity 60 multicenter clinical 60 Immunotherapeutic 60 Exelixis XL# 60 catheter occlusion 60 Truvada tablets 60 Sevelamer 60 CIMZIA TM 60 NO# [002] 60 randomized controlled clinical 60 Prospective Randomized Trial 60 CURRENT OASIS 7 60 prospective nonrandomized 60 Rheumatoid Arthritis RA 60 recurrent malignant glioma 60 Stereotactic Body Radiation Therapy 60 Phase 2b Trial 60 observational cohort 60 Tyrima 60 Prostate Cancer Prevention 60 REYATAZ ritonavir 60 lacosamide 60 Insulin Glargine 60 ABC/3TC 60 PEGINTRON TM 60 CHARM Added 60 glucocorticoid induced osteoporosis 60 FDA Approvals 60 Initiate Phase 60 randomized clinical 60 CBLC# 60 Ixempra 60 noscapine 60 multicenter Phase III 60 Unstable Angina 60 Adjunctive 60 Phase III placebo controlled 59 Multicenter Randomized 59 Investigational Treatment 59 Invasive Fungal Infections 59 postmenopausal osteoporotic women 59 Intravesical 59 Anthracycline 59 APEX PD 59 By JENNIFER LEARN 59 mycophenolate mofetil 59 Renal Cell Carcinoma RCC 59 TASKi3 59 candesartan cilexetil 59 CLOTS 59 APPRAISE 59 erlotinib Tarceva ® 59 BENICAR 59 BR.# 59 opioid induced bowel dysfunction 59 Pyridorin 59 ATTRACT 59 trials RCTs 59 Gemzar ® 59 label multicenter 59 Benign Prostatic Hyperplasia 59 zonisamide SR 59 Cutaneous T 59 phase IIb 59 Teva Provides Update 59 Anti Tumor 59 AEGR 59 IIa Clinical Trial 59 afatinib 59 pyridostigmine 59 Abciximab 59 evaluating REVLIMID 59 CAMMS# 59 Malignant Melanoma 59 phase IIb clinical 59 lanthanum carbonate 59 Improves Survival 59 FIX HF 5 59 Study Showed 59 Lubiprostone 59 imatinib mesylate Gleevec 59 Confirmatory Phase 59 Renal Cell Carcinoma 59 cinacalcet 59 SPIRIT IV 59 Radiofrequency Ablation 59 Follicular Lymphoma 59 Cloretazine 59 TO AVOID PREGNANCY WHILE 59 Dapagliflozin 59 multicentre prospective 59 ACCORD Lipid 59 CANCIDAS 59 Phase IIA 59 NOXAFIL 59 Clinical Efficacy 59 TG MV 59 HORIZONS AMI trial 59 superficial bladder cancer 59 IRESSA 59 ULORIC 59 ARIMIDEX 59 ThermoDox R 59 WallFlex Biliary RX 59 Randomized Controlled 59 ISEL 59 Metastatic Renal Cell Carcinoma 59 Safinamide 59 Watchful Waiting 59 irbesartan 59 metastatic malignant 59 interferon gamma 1b 59 Adult Stem Cell Therapy 59 thorough QT 59 multicenter Phase 59 BEXXAR Therapeutic Regimen 59 SPIRIVA ® 59 Adjuvant Breast Cancer 59 Multicenter Randomized Double 59 Rotavirus Vaccine 59 CT Angiography 59 Investigational Drug 59 BARACLUDE ® 59 Dose Escalation 59 Reduces Mortality 59 Phase III randomized 59 Antitumor Activity 59 TMS Therapy 59 Inhaled Corticosteroids 59 phase III ACCLAIM 59 HDAC Inhibitor 59 Endovascular System 59 Bayer HealthCare Onyx Pharmaceuticals 59 Adverse Event 59 MEVACOR 59 Renal Cancer 59 Castration Resistant Prostate Cancer 59 Xeloda ® 59 Patients Undergoing 59 NATRECOR ® 59 Metastatic Melanoma 59 Endovascular Valve Edge 59 ACUITY trial 59 HCV Protease Inhibitor 59 Neoadjuvant Chemotherapy 59 Phase 1b Clinical Trial 59 mycophenolate mofetil MMF 59 PRE SURGE 59 randomized controlled Phase 59 Posaconazole 59 orally inhaled migraine 59 Simulect 59 Oral Insulin 59 Renal Function 59 Apaziquone 59 morphometric vertebral fractures 59 NDA Submission 59 Statin Therapy 59 landmark ATHENA 59 INTELENCE 59 CCX# B 59 prucalopride 59 topiramate Topamax 59 vidofludimus 59 evaluating tivozanib 59 clevidipine 59 Candesartan 59 Symptom Relief 59 Ophena TM 59 CONQUER OB 59 Therapy Evaluation 59 abacavir Ziagen 59 gastrointestinal stromal tumors GIST 59 Glufosfamide 59 ECASS 59 prospective observational cohort 59 GAMMAGARD 59 Biolimus A9 59 PERSEUS 59 alfa 2a 59 Controlled Study 59 Phase IIb Clinical Trial 59 Multicenter Phase 59 Dabigatran etexilate 59 sorafenib tablets 59 phase IIb trial 59 Medoxomil 59 Hepatitis C Genotype 59 substudy 59 bosentan Tracleer 59 candesartan 59 metastatic colorectal 59 longitudinal cohort study 59 Metabolic Efficiency 59 Phase #/#a 59 raloxifene Evista 59 Vicriviroc 59 cilostazol 59 Phase IIIb study 59 Teriflunomide 59 Dalbavancin 59 clinical pharmacology studies 59 neratinib 59 Quetiapine 59 MEK Inhibitor 59 HYVET 59 thalidomide Thalomid 59 donepezil Aricept 59 HIV HCV coinfected 59 ISENTRESS 59 CYT# QbG# 59 HyACT 59 Potent Inhibitor 59 Bone Mineral Density 59 Pivotal Phase II 59 Echocardiographic 59 BR.# study 59 Ticagrelor 59 Unresectable 59 CUSTOM II 59 Parathyroid Hormone 59 Localized Prostate Cancer 59 Minimally Invasive Treatment 59 Intracranial Aneurysms 59 CIMZIA ™ 59 Proves Effective 59 keloid scarring 59 Sorafenib 59 Tarceva TM 59 Antipsychotic 59 Diabetic Macular Edema DME 59 fenretinide 59 atazanavir sulfate 59 Prostate Lung Colorectal 59 Peripheral Arterial 59 paricalcitol 59 Epratuzumab 59 Hypertensive Patients 59 NCCTG N# 59 Lung Injury 59 gemcitabine carboplatin 59 Vasogen Celacade 59 landmark ATHENA trial 59 Molecular Weight Heparin 59 Heart Failure Patients 59 paclitaxel poliglumex 58 biologic DMARD 58 ST Elevation Myocardial 58 Remission Maintenance 58 COSIRA trial 58 TYKERB 58 BIBW 58 IMPACT DCM 58 liposomal doxorubicin 58 Quinamed 58 Prostate Cancer Outcomes 58 Pegylated Liposomal Doxorubicin 58 AA Amyloidosis 58 GSK# [001] 58 UPLYSO 58 Antihypertensive 58 MADIT 58 Lupus Drug 58 oral rivaroxaban 58 ximelagatran 58 Nebulized 58 boosted protease inhibitor 58 TYGACIL 58 REVIVE Diabetes 58 Ranibizumab 58 transthyretin TTR mediated amyloidosis 58 ezetimibe simvastatin 58 Tolvaptan 58 Uterine Fibroid 58 AZILECT ® 58 Platinol ® 58 Chemoradiation 58 Dupuytren Contracture 58 pharmacokinetic PK study 58 patients undergoing percutaneous 58 Celecoxib 58 Hsp# Inhibitor 58 Bevacizumab 58 Lung Cancer Survival 58 carotid artery stenting 58 Carotid Artery Stenting 58 Trial NLST 58 Hepatic Encephalopathy 58 Replacement Therapy 58 Randomized Phase III 58 Adjunctive Therapy 58 familial amyloidotic polyneuropathy FAP 58 everolimus eluting stent 58 tolvaptan 58 chemoradiation therapy 58 Prevent Stroke 58 PRIALT 58 CLINICAL PHARMACOLOGY 58 Drug Eluting Stent System 58 Clinical Antipsychotic Trials 58 See WARNINGS 58 Serious Adverse Events 58 inhibitor RG# 58 Pelvic Organ Prolapse 58 PREVAIL 58 First Patient Dosed 58 Minimally Invasive Procedure 58 Elagolix 58 Appears Safe 58 Ramelteon 58 AOD# [002] 58 sulodexide 58 Reduced Risk 58 Carotid 58 strontium ranelate 58 Fabry Disease 58 forodesine 58 Inhalation Solution 58 RoACTEMRA 58 ABSORB clinical 58 BARACLUDE R 58 Microplasmin 58 biliary tract cancer 58 Omacetaxine 58 longitudinal observational study 58 ASSERT 58 interferon beta 1b 58 bevacizumab Avastin ® 58 Pfizer Sutent 58 atherothrombotic events 58 Clinical Trial Data 58 stage IIIB 58 galiximab 58 GetGoal Phase III 58 Interferon beta 1a 58 label multicenter Phase 58 Microwave Ablation System 58 Amrubicin 58 Actimmune ® 58 PEGylated interferon beta 1a 58 recurrent GBM 58 chemoradiotherapy 58 Bone Metastases 58 HCV Genotype 58 ILLUSTRATE 58 IFN alfa 58 MGd 58 Randomized Controlled Trial 58 Phase IIa Clinical Trial 58 SYNTAX 58 corticosteroid dexamethasone 58 GOUT 58 LEXIVA r 58 Uterine Fibroids 58 miconazole Lauriad ® 58 SCH # 58 Epidermal Growth Factor Receptor 58 Aggressive Drug Evaluation 58 ACEIs 58 J Am Coll 58 Successfully Completes Phase 58 CALGB # [001] 58 Systolic Hypertension 58 BOLDER 58 Cognitive Impairment 58 Zarnestra 58 Analytical Tool 58 Heterozygous Familial Hypercholesterolemia 58 Peginterferon Alfa 2a 58 retinal vein occlusion 58 Shows Promise Against 58 cathepsin K inhibitor 58 Aurora Kinase 58 Initiate Phase II 58 Critical Limb Ischemia CLI 58 VICTOR E1 58 Pharmacologic 58 protease inhibitor PI 58 Angiographic 58 Improve Survival 58 AIR2 Trial 58 atorvastatin #mg 58 Single Dose 58 docetaxel Taxotere R 58 FOSRENOL R 58 efavirenz EFV 58 prasugrel Effient 58 Interferon Gamma 58 ORACLE MS 58 recurrent NSCLC 58 analgesic efficacy 58 acute coronary syndromes ACS 58 Osteoporosis Treatment 58 Glycopyrrolate 58 NEVO 58 Malignant Glioma 58 prospective observational 58 ACTOS ® 58 Evaluation WISE 58 eluting stent 58 multicentre randomized double 58 intravesical infusion therapy 58 Solid Tumors 58 BOLDER II 58 ELONVA 58 Hormone Receptor Positive 58 Chronic Hepatitis C 58 GRASPA ® 58 Delcath Phase III 58 rt PA 58 TAXUS VI 58 REVEAL Registry 58 FOLOTYN ® 58 TPV r 58 ALN HPN 58 Acute Liver Failure 58 Heart Transplant Recipients 58 AZILECT R 58 Placebo Controlled 58 pharmacodynamic effects 58 Non Responders 58 Abbott Trilipix 58 recurrent venous thromboembolism 58 Antiangiogenic 58 Stenting Trial 58 Clinical Evaluation 58 Demonstrates Positive 58 ug dose 58 Cardiac Resynchronization Therapy 58 ENDEAVOR 58 Ropinirole 58 Chronic Hepatitis B 58 ARCALYST ® rilonacept 58 Osteoarthritis Patients 58 CALERIE 58 Zoledronic Acid 58 Bare Metal Stents 58 cilengitide 58 PKC# 58 PREDICTIVE 58 INTEGRILIN R 58 atypical Hemolytic Uremic Syndrome 58 Radical Prostatectomy 58 Treatment Regimen 58 sirolimus eluting 58 Phase IIb III 58 brivaracetam 58 Lung Cancer Screening 58 PREVENT IV 58 dosing cohorts 58 Efficacy Study 58 tipifarnib 58 Community Acquired Pneumonia 58 Risk Stratification 58 Non Inferiority 58 teriflunomide 58 Initiates Clinical Trial 58 deferiprone 58 ONCONASE R 58 Valdoxan 58 samarium Sm 58 Randomized Double Blind Placebo 58 EXPLORE Xa 58 dose atorvastatin 58 histologically proven 58 metastatic androgen independent 58 treatment naïve genotype 58 Clinical Trial Results 58 neurologic progression 58 Elderly Patients 58 Pafuramidine 58 idraparinux 58 Sustained Efficacy 58 Brain Metastases 58 Lamotrigine 58 mapatumumab 58 Novel Inhibitor 58 EGFR HER2 58 pravastatin Pravachol 58 Allergic Rhinitis 58 Sirolimus Eluting 58 VICTOR E3 58 Atacand ® 58 Diamyd Medical Diamyd 58 endometrial hyperplasia 58 Randomized Clinical Trials 58 Suicidality 58 adalimumab 58 briakinumab 58 RhuDex 58 Zolinza 58 symptomatic VTE 58 Endarterectomy 58 BAY #-# 58 PROMUS R 58 APRICOT 58 Topline Results 58 Cholesterol Lowering Drug 58 Screening Trial DMIST 58 LEVAQUIN 58 Phase 1b clinical trials 58 LAB CGRP 58 SABCS 58 Clinical Outcomes 58 double blinded placebo 58 Benign Prostatic Hyperplasia BPH 58 Angiotensin Converting Enzyme 58 Intervention Trial GAIT 58 Elvitegravir 58 HMG CoA reductase inhibitors 58 divalproex sodium 58 Aplidin R 58 gadobutrol 58 NAVISTAR R 58 Pediatric Patients 58 complement inhibitor eculizumab 58 alendronate Fosamax 58 serotonin norepinephrine reuptake inhibitor 58 posaconazole 58 LibiGel Phase III 58 Congestive Heart Failure 58 colorectal adenoma 58 randomized Phase III 58 TAXUS IV 58 celecoxib Celebrex